KRAS

FDA approves breakthrough pancreatic cancer drug – an oncologist explains how daraxonrasib nearly doubles survival

<figure><img src="https://images.theconversation.com/files/756352/original/file-20260826-50-i3i6eu.jpg?ixlib=rb-4.1.1&rect=142%2C0%2C1977%2C1318&q=45&auto=format&w=1050&h=700&fit=crop" /><figcaption><span class="caption">Pancreatic cancer has been notoriously difficult to target and treat.</span> <span class="attribution"><a class="source" href="https://www.gettyimages.com/detail/photo/cancer-detection-royalty-free-image/1477214805">wildpixel/iStock via Getty Images Plus</a></span></figcaption></figure><p>For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about <a href="https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html">97% died within five years</a> of their diagnosis. </p> <p>Pancreatic cancer is so deadly in part because there are no effective screening tests, and it <a href="https://